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Stickler syndrome is a dominantly inherited disorder characterized by arthropathy, midline clefting, hearing loss,
midfacial hypoplasia, myopia, and retinal detachment. These features are highly variable both between and within
families. Mutations causing the disorder have been found in the COL2A1 and COL11A1 genes. Premature ter-
mination codons in COL2A1 that result in haploinsufficiency of type II collagen are a common finding. These
produce a characteristic congenital “membranous” anomaly of the vitreous of all affected individuals. Experience
has shown that vitreous slit-lamp biomicroscopy can distinguish between patients with COL2A1 mutations and
those with dominant negative mutations in COL11A1, who produce a different “beaded” vitreous phenotype. Here
we characterize novel dominant negative mutations in COL2A1 that result in Stickler syndrome. Both alter amino
acids in the X position of the Gly-X-Y triple-helical region. A recurrent R365C mutation occurred in two unrelated
sporadic cases and resulted in the membranous vitreous anomaly associated with haploinsufficiency. In a large
family with linkage to COL2A1, with a LOD score of 2.8, a unique L467F mutation produced a novel “afibrillar”
vitreous gel devoid of all normal lamella structure. These data extend the mutation spectrum of the COL2A1 gene
and help explain the basis for the different vitreous phenotypes seen in Stickler syndrome.
Introduction
Stickler syndrome (hereditary arthro-ophthalmopathy
[MIM 108300, MIM 184840, and MIM 120280]) is a
dominantly inherited vitreoretinopathy and chondrodys-
plasia caused by mutations in COL2A1 and COL11A1,
the genes for types II and XI collagen (Ahmad et al.
1991; Richards et al. 1996). Systemic features such as
arthropathy, midline clefting, hearing loss, and midfacial
hypoplasia are highly variable. The incorporation of a
premature termination codon into the open reading
frame of COL2A1 transcripts, by either frameshift, mis-
splicing, or point mutations is a common feature of the
disorder (Ahmad et al. 1991; Brown et al. 1992, 1995;
Williams et al. 1996; Richards et al. 2000) and causes
haploinsufficiency of type II collagen. In our experience,
this results in a characteristic “membranous” congenital
anomaly in the vitreous (Scott 1989; Snead et al. 1994;
Snead and Yates 1999; Richards et al. 2000; authors’
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unpublished results). This anomaly is also present in
patients with mutations in exon 2, which result in a
predominantly ocular disorder (Richards et al. 2000).
This feature distinguishes Stickler syndrome due to
COL2A1 mutations from a similar disorder caused by
mutations in COL11A1, which results in a different vit-
reous phenotype (Richards et al. 1996; Martin et al.
1999; Snead and Yates 1999).
Types II and XI collagen are members of the family
of fibrillar collagens, which also comprises types I, III,
and V collagen. These molecules contribute to the
strength and shape of the tissues in which they are ex-
pressed and are encoded by at least nine different genes
(Prockop and Kivirikko 1995). Type I collagen predom-
inates in bone, type II collagen in cartilage and vitreous,
and type III collagen in blood vessels. Types V and XI
collagen are quantitatively minor collagens that have a
role in regulating the diameter of collagen fibrils (Li et
al. 1995; Marchant et al. 1996). Increasing the levels
of types V and XI with respect to the more abundant
collagens results in fibrils with a smaller diameter. Thus,
in tissues in which transparency is important, such as
cornea and vitreous, greater expression of types V and
XI collagen results in thinner collagen fibrils. All fibrillar
collagens have a long uninterrupted repetitive amino
acid sequence of glycine-X-Y, which forms the extended
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collagen triple helix. It is obligatory that glycine
occupies every third position within the helix, since
other amino acids disrupt the correct conformation of
the helix. Defects in the genes for fibrillar collagens
are known to cause a variety of inherited disorders
(Prockop and Kivirikko 1995; Vikkula et al. 1995;
Nicholls et al. 1996; Richards et al. 1996;Michalickova
et al. 1998)—osteogenesis imperfecta (COL1A1 and
COL1A2), some forms of chondrodysplasias, including
Stickler syndrome (COL2A1 and COL11A1), otospon-
dylomegaepiphyseal dysplasia (COL11A2), and some
types of Ehlers-Danlos syndrome (COL1A1, COL1A2,
COL3A1, COL5A1, and COL5A2). There are many
examples of mutations that result in the substitution of
a helical glycine residue by a bulkier amino acid, causing
the aforementioned disorders (Kuivaniemi et al. 1997).
Such mutations in the abundant collagens have been
shown to reduce secretion of the mutant molecules and
to lead to intracellular degradation (Prockop and Ki-
virikko 1995). Similar mutations in COL11A1 proba-
bly have the same effect on type XI collagen, resulting
in the irregularly thickened fiber bundles seen clinically
in the vitreous of patients who have such alterations.
Well-characterized mutations altering X- or Y-posi-
tion amino acids are much rarer, but the substitution
of cysteine into the X or Y position of the type II col-
lagen helix has been reported. This amino acid is usually
absent from the helical region of all fibrillar collagens,
except type III, in which it occurs at the extreme car-
boxy-terminal end of the molecule.
The phenotypes caused by different mutations in
COL2A1 range from severe achondrogenesis II through
spondyloepiphyseal dysplasia (SED) congenita (SEDC),
Kniest dysplasia to the milder Stickler syndrome and
precocious arthritis. The most severe forms result from
glycine substitutions and other, more disruptive muta-
tions. Three different cysteine substitutions result in a
range of phenotypes—namely, familial osteoarthritis,
mild SED, or SEDC (Ala-Kokko et al. 1990; Chan et
al. 1993; Williams et al. 1993), whereas a fourth pro-
duces a Stickler-like syndrome (Ballo et al. 1998). The
substitution of a cysteine into the a1(I) and a2(XI) col-
lagen chains produces relatively mild phenotypes, com-
pared with glycine substitutions in the same a chains
(McGuirt et al. 1999; Nuytinck et al. 2000).
In this report we characterize a fifth example of a
cysteine substitution in type II collagen and show that
it results in the same vitreous phenotype as that caused
by nonsense mutations. In contrast, a unique L467F
mutation in the X position of the type II collagen helix
results in a novel vitreous phenotype that is also dif-
ferent from that caused by mutations in COL11A1.
These data extend the mutation spectrum of the
COL2A1 gene and help to explain the basis for the
different vitreous phenotypes seen in Stickler syndrome.
Patients, Material, and Methods
Clinical Examination
Patients and pedigrees were identified from the Vit-
reous Clinic database at Addenbrooke’s Hospital. We
obtained informed written consent in all cases and prior
ethical approval (LRC92/019) for the study. The diag-
nostic criteria used for Stickler syndrome were as pub-
lished elsewhere (Snead and Yates 1999)—(1) congenital
vitreous anomaly and (2) any three of the following fea-
tures:
a. myopia with onset at age !6 years;
b. rhegmatogenous retinal detachment or paravas-
cular pigmented lattice retinopathy;
c. joint hypermobility with abnormal Beighton score
(with or without radiological evidence of joint
degeneration);
d. audiometric confirmation of sensorineural hearing
defect;
e. midline clefting.
Physical Examination
All patients were examined subjectively and objec-
tively using methods described elsewhere (Richards et
al. 2000). In brief, a subjective assessment was made of
the nonquantifiable parameters retrognathia and ante-
version of nares. All other parameters were measured
objectively, according to a standardized method (Hall et
al. 1989). Anteroposterior and lateral facial photographs
at a standardized scale of 1:8 and photographs of both
hands at a scale of 1:10 were taken using a Nikon FM2
camera with Micro Nikon 105-mm medical lens and
Kodachrome 64 film at F16. A 1-cm grid was printed
and then photographed at a scale of 1:8, to match the
facial films, and at a scale of 1:10, to match the hand
views. Clinical measurements of outer canthal distance,
inner canthal distance, philtrum length, and middle-fin-
ger length were also recorded at the time of initial ex-
amination. These were used subsequently to test the ac-
curacy of the method of photographic calibration.
Control measurements of inner and outer canthal dis-
tance, interpupillary distance, and philtrum length in 20
unaffected siblings and 60 age-matched controls (re-
cruited from the general ophthalmic clinic) were also
recorded.
By dual projection of identically calibrated projectors,
the matched scales were superimposed over each facial
view in turn, so that the quantifiable facialmeasurements
could be made. This was repeated using the matched
scale for the hand views. All measurements were made
according to criteria published elsewhere (Hall et al.
1989).
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Clinical Features
Pedigree MS12.—The proband was referred to the
Vitreoretinal Service at age 4 years, having been found
to be myopic at age 1 year. Cycloplegic refraction re-
vealed extreme myopia in both eyes: OD 23.50/
; OS . There was2.00# 90p 6/9 23.50DSp 6/36
a moderate left esotropia for near and distance vision.
Anterior-segment examination was unremarkable, with
normal anterior-chamber drainage-angle development
and clear crystalline lenses. Vitreous examination con-
firmed the presence of the type 1 membranous vitreous
anomaly, set well back toward the posterior segment of
both eyes. Both retinae were attached, with no peripheral
lattice retinopathy. The optic disks were normal, with
no signs of “myopic” peripapillary chorioretinal atro-
phy. At age 4 years, the patient underwent bilateral con-
tiguous 360 prophylactic retinal cryotherapy. The pa-
tient is now age 17 years, and vision has remained stable
in both eyes. Results of cardiovascular examination and
echocardiography were normal. Stature is normal. Au-
diometric testing at age 7 years confirmed mild, bilateral
sensorineural deafness, which has remained stable. Joint
hypermobility has been present since early childhood.
Formal testing confirmed a Beighton (1993) score of 6/
9. On radiological screening, there wasminimal evidence
of spondyloepiphyseal dysplasia or degenerative joint
disease. The patient exhibited the classical facial features
of Stickler syndrome, with midfacial hypoplasia and a
short and underdeveloped nasal bridge with mildly an-
teverted nares (fig. 1A–C). There was no evidence of
midline clefting.
Pedigree MS16.—The proband was adopted by foster
parents, and a full family history is unavailable. She was
born at 38 wk gestation, weighing 2.94 kg. There was
a paternal history of congenital heart disease, and heart
failure was diagnosed at age 3 d, with pulmonary-valve
stenosis and a patent ventriculoseptal defect. At age 2
years, the patient underwent surgery to repair the ven-
triculoseptal defect and to relieve the valvular stenosis.
At age 5 years, the patient underwent a major craniofa-
cial reconstructive procedure to correct mid- and upper-
facial hypoplasia and nasal hypoplasia. Three years later,
she developed a secondary hydrocephalus requiring a
ventriculoperitoneal shunt. The shunt was revised and
replaced in 1999.
Myopia had been diagnosed at age 6 years, and the
patient suffered a giant-tear retinal detachment in her
right eye that was not successfully repaired. The follow-
ing year, the right eye was enucleated. A year later, the
patient was referred to the Vitreoretinal Service at Ad-
denbrooke’s Hospital, with a tentative diagnosis of
Crouzon syndrome. Examination of the left eye under
cycloplegic refraction confirmed extreme myopia: OS
. Anterior-segment examination32.50/ 2.00# 90
showed a wedge-shaped cortical lens opacity (Scott
1989; Seery et al. 1990). Assessment of the craniofacial
phenotype was difficult because of previous craniofacial
surgery and hydrocephalus. However, the extreme myo-
pia, sectorial cortical lens opacity, previous giant retinal
tear, joint laxity, mixed conductive and sensorineural
deafness, and midline cleft were all suggestive of Stick-
ler syndrome rather than Marshall syndrome (MIM
154780) (table 1). This was further supported by the
presence of the type 1 membranous vitreous anomaly
(STL1 [MIM 108300] [Snead et al. 1994]), which is not
a feature of Marshall syndrome. The patient underwent
contiguous 360 retinal cryotherapy for multiple 360
retinal tears in the left eye. Vision remains stable, and
the left retina remains attached after 13 years’ follow-
up.
The patient has a history of serous otitis media, with
multiple grommet procedures in the past. In addition,
audiometric testing confirmed mild, bilateral sensori-
neural deafness that has since remained stable. Joint hy-
permobility had been noted since early childhood. For-
mal testing revealed a Beighton score of 7/9. The patient
is now age 20 years and is under orthopedic review
because of premature arthritis that principally affects the
ankles and knees. The patient exhibits the typical facial
features of Stickler syndrome, with midfacial hypoplasia
and a short and underdeveloped nasal bridge with an-
teverted nares. There is a high arch to the palate, and
the ears are “low set” (fig. 1D–F).
Pedigree MS25.—The proband from pedigree MS25
was identified using the standardized diagnostic protocol
given above. However, although in this pedigree all af-
fected individuals exhibited the major criterion of ab-
normal vitreous architecture, systemic involvement was
found to be highly variable and generally mild. The clin-
ical phenotype is illustrated by individual III-7 (fig.
1G–I). Strikingly, no individual in this pedigree exhib-
ited the type 1 membranous vitreous anomaly. Instead,
an “afibrillar” vitreous gel devoid of all normal lamella
structure filled the entire posterior segment. No individ-
ual exhibited the “beaded” vitreous phenotype associ-
ated with mutations in the COL11A1 gene (Richards et
al. 1996; Martin et al. 1999; authors’ unpublished data).
The three distinctive vitreous phenotypes, together with
a normal one, for comparison, are shown in figure 2A–D.
In affected individuals, ophthalmic, aural, skeletal,
and orofacial features were assessed and compared with
age- and sex-matched controls, as described elsewhere
(Richards et al. 2000). The results are summarized in
table 1, which also includes individuals MS12 and
MS16, for comparison.
Linkage Analysis
Linkage analysis was performed in family MS25, for
markers close to the COL2A1, COL11A1, COL11A2,
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Figure 1 Clinical phenotypes. A–C, MS12, age 17 years, showing mild nasal-root hypolasia and moderate midfacial hypoplasia and
slender digits. D–F, MS16, age 14 years. Note anteverted nares and nasal-root hyoplasia and joint laxity. G–I, III-7, MS25, age 29 years. Note
well-developed nasal bridge and root, moderate midfacial hypoplasia, and slender digits.
and COL5A2 genes, as described elsewhere (Martin et
al. 1999). Additional polymorphic markers were used
to investigate the relationship betweenMS12 andMS16.
Amplification and Sequencing
Regions of the COL2A1 gene were amplified and se-
quenced, as described elsewhere (Richards et al. 2000).
COL2A1 cDNAwas amplified after two rounds of PCR,
essentially as described elsewhere forCOL11A1 (Martin
et al. 1999). Reverse transcription of RNA from cultured
skin fibroblasts was performed using Superscript II (Stra-
tagene). After an initial 40 cycles of amplification, re-
action products were purified and reamplified with the
same sense primer and an antisense primer internal to
that used in the primary amplification. Primers used for
amplification are described in table 2. To amplify a re-
gion containing exon 42, primers X36F, X53R, and
X44R were used. This reaction product was sequenced
with X43R. Similarly, a region containing exon 31 was
amplified with X20F, X43R, and X34R and was se-
quenced with X33R. A region containing exon 26 was
amplified with X20F, X34R, and X33R and was se-
quenced with X24F. All primers were based on the se-
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Table 1
Phenotypes
FAMILY
AND
SUBJECT
OCULAR PHENOTYPE ARTICULAR PHENOTYPE
AURAL
PHENOTYPE OROFACIAL PHENOTYPEa
Myopiab
Rhegmatogenous
Retinal
Detachmentc
Joint
Laxityd
Radiological
Joint
Abnormality
Hearing
Losse
Midfacial
Hypoplasia
Abnormal
Nasal
Development
Midline
Cleftingf
MS12:
II-1  NA 3 0  (S)   0
MS16:
II-1  1 3   (M)   
MS25:
II-1  2 0 0  (S) 0 0 0
II-3  NA 0  0  0 0
II-5  2 0 0  (S) 0 0 0
III-1  2 0 0 0 0  0
III-3  1 0 0 0 0 0 
III-5  NA 2 0  (S) 0 0 
III-7  0 0 0 0  0 0
III-10  NA 0 0 0  0 0
IV-2  NA 2 0 0 0  0
a Assessed according to age/sex-matched control (Hall et al. 1989)
b  p 5 to 10D and  p 110D.
c 0 p no retinal detachment; 1 p single eye; 2 p both eyes; NA p not applicable because of prophylactic treatment.
d Beighton score p 1, 2, or 3 more than that in age/sex-matched controls (Beighton 1993).
e  p Mild (30 dB);  p moderate (30–60 dB); and  severe p (160 dB), compared with age/sex matched controls
(data not shown). S p sensorineural; M p mixed.
f  p Bifid uvula;  p high-arch palate;  p cleft-palate repair.
quence for the COL2A1 gene (Genome Database ac-
cession number L10347)
Family Testing
Restriction digestion with the enzyme BbvI was used
to test the family and controls for the R365C mutation.
A region of COL2A1 containing exon 26 was amplified
and incubated with the enzyme at 37C for 16 h. The
products were analyzed by electrophoresis in an 8%
polyacrylamide gel, stained with ethidium bromide, and
viewed under UV light. Hybridization of allele-specific
oligonucleotides was also used, to examine possible mo-
saicism in MS12 and MS16. The mutant allele was
cloned into the Bluescript vector (Stratagene). Amplified
mutant product was mixed with an equal amount of
normal PCR product, to produce a complete heterozy-
gote. Blood and skin were used to amplify DNA from
affected individuals, as were blood samples from family
members and normal controls. Amplified products were
slot blotted in triplicate, hybridized to allele-specific
oligonucleotides (cactggccgccctgg R365 and cactggctg-
ccctgg C365), and washed according to conditions used
by Wood et al. (1985). A single dideoxynucleotide-se-
quencing reaction was used to test for the L467F mu-
tation in MS25 and controls, as described elsewhere
(Richards et al. 2000).
Results
Slit-lamp examination of three cases of Stickler syn-
drome identified two sporadic cases (pedigrees MS12
and MS16) with the congenital membranous anomaly
characteristic of mutations in COL2A1. In the third
case, a large family (MS25) had an unusual vitreous
phenotype in which an afibrillar vitreous gel devoid of
all normal lamella structures filled the posterior segment.
This appearance also differed from the phenotype as-
sociated with mutations in COL11A1 (fig. 2). Systemic
features in MS25 were relatively mild (fig. 1 and table
1). In family MS25, linkage analysis that used the
COL2A1 3′ VNTR was uninformative. However, flank-
ing markers D12S85 and D12S1703 were consistent
with COL2A1’s being the disease locus, with LOD
scores of 2.4 and 2.8, respectively, at 0 recombination.
Linkage to COL11A1, COL11A2, and COL5A2 was
excluded by recombination between affected individuals
and polymorphic markers (data not shown). Loci were
excluded if affected individuals were recombinant for
markers very close to the candidate genes or if affected
individuals had inherited different haplotypes for flank-
ing markers.
After DNA amplification, exon sequencing of
COL2A1 identified identical mutations in the two spo-
radic cases. Each had a CrT base change in exon 26,
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Figure 2 Vitreous phenotypes in Stickler syndrome. A, Mem-
branous congenital vitreous anomaly seen in MS12 and MS16. Note
vestigial gel occupying retrolental space and bordered by a distinct
folded membrane (arrows). B, Beaded congenital vitreous anomaly:
COL11A1 mutation (see Martin et al. 1999). Note irregularly thick-
ened fiber bundles, giving a string-of-pearls appearance (arrows). C,
Afibrillar congenital vitreous anomaly seen in MS25. Note complete
absence of visible fiber bundles.D,Normal vitreous appearance. Note
healthy compact homogenous fibrillar array.
Table 2
Primer Sequences Used for RT-PCR
Primer Position Sequence
20F Exon 20 sense CAGATGGAATTCCTGGAGCCAAAG
24F Exon 24 sense CAAGATGGTCTGGCAGGTCCCAAG
36F Exon 36 sense CCAGCTGGTGCTAACGGCGAGAAG
33R Exon 33 antisense CTGGGCACCGGGAGAGCCACGTTC
34R Exon 34 antisense AGCGATACCAGCTGCTCCCCTCTC
43R Exon 43 antisense AGGGAATCCTCTCTCACCACGTTG
44R Exon 44 antisense GGGTTCACCTGCAGGACCCGTCAG
53R Exon 53 antisense TGAACCTGCTATTGCCCTCTGCCC
which converted a codon for arginine to cysteine, at
position 365 of the collagen helix (fig. 3). According to
convention, the initial glycine of the collagen triple helix
was assigned to position 1. The R365C CrT mutation
created a new BbvI restriction site; this was used to
confirm that the mutation was absent in the DNA from
both unaffected parents in MS12 (fig. 4A) and from an
additional 25 controls (50 chromosomes; data not
shown). Slot-blot analysis that used allele-specific oli-
gonucleotides and PCR products amplified from blood
and cultured skin cells did not indicate mosaicism in
either affected individual (data not shown). Analysis of
polymorphic markers confirmed parentage inMS12 and
confirmed that family MS16 was unrelated to this fam-
ily (data not shown). Sequencing of exons 2–54, am-
plified from an affected individual in MS25, identified
a CrT change in exon 31, which converted leucine to
phenylalanine at amino acid position 467 (fig. 3). For
MS25, a single dideoxynucleotide-sequencing reaction
was used to demonstrate that all affected individuals
had inherited the L467F mutation (fig. 4B). In addition
to unaffected family members, 50 controls (100 chro-
mosomes; data not shown) were shown to lack the CrT
base change.
These mutations were unlike the usual haploinsuffi-
ciency mutations that cause Stickler syndrome and
should exert a dominant negative effect. Previous ob-
servations have shown that premature termination co-
dons can lead to the degradation of the mRNA from
the mutant allele (Baserga and Benz 1988; Maquet
1995). We compared the cDNA sequences of these three
cases of missense mutations with cDNA amplified from
an individual with a nonsense mutation in exon 42
(MS20; previously characterized by Richards et al.
[2000]). The cDNA sequence from the individual with
a COL2A1 nonsense mutation demonstrated the loss
of heterozygosity that would be expected if mRNA tran-
scribed from the mutant allele were specifically de-
graded (fig. 5). However, cDNA from MS12, MS16,
and MS25 was heterozygous for the mutations seen in
genomic DNA (data shown only for MS16 and MS25),
which supports the notion of a dominant negative mu-
tation causing the disorder in these families.
Discussion
Stickler syndrome is a clinically and genetically hetero-
geneous disorder (Francomano et al. 1987; Scott 1989,
1998; Fryer et al. 1990; Vintiner et al. 1991; Brunner
et al. 1994; Richards et al. 1996; Sirko-Osadsa et al.
1998; Annunen et al. 1999; Martin et al. 1999). A recent
study of patients with Stickler syndrome, and of those
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Figure 3 COL2A1 genomic sequencing. The heterozygous (ar-
rows) mutation-containing sequences obtained from affected individ-
uals in MS12, MS16, and MS25 are shown under the normal sequence
(N). Intron sequences are in lowercase, and coding sequences are in
uppercase.
Figure 4 DNA analysis of families. A, DNA containing exon
26, which was amplified from MS16 (1) and MS12 (2–5) and digested
with BbvI. Extra bands in samples from affected individuals, visualized
after electrophoresis, are marked with arrows. Undigested DNA (lane
U) and standard size markers (bp) were included on the gel. B, Results
of [33P]dideoxynucleotide sequencing reaction, which was used to de-
tect the mutation in MS25. Samples correspond to the pedigree shown
above the gel. Family members not included in the analysis are situated
on either side of the gel. Nucleotide numbers correspond to the com-
plete COL2A1 gene sequence (Genome Database accession number
L10347).
with the closely relatedMarshall syndrome, showed that
many clinical features are shared by the two, but that
some are more common to Marshall syndrome (Annu-
nen et al. 1999). We have noted that hearing loss is more
common in patients who have mutations in COL11A1,
whereas cleft palate is more common in patients who
have COL2A1 mutations (Snead et al. 2000). Certain
features, such as abnormal frontal sinuses, intracranial
ossifications, and thickened calvarium, were specific to
patients with Marshall syndrome who have COL11A1
mutations (Annunen et al. 1999). However, these were
examined only in three cases of Marshal syndrome and
two cases of Stickler syndrome. In addition, no datawere
given regarding vitreous phenotype, which is a key fea-
ture of the Stickler syndrome, so that a definitive dif-
ference between the two syndromes remains to be
resolved.
The vitreous phenotype can be an important indi-
cation of which genetic locus bears the mutation (Snead
et al. 1994; Snead and Yates 1999; Richards et al. 2000).
The vitreous also provides a unique opportunity to ob-
serve the effect of collagen mutations in vivo. Although
the vitreous is 98% water, its collagen, proteoglycan,
and cellular components impart a characteristic struc-
tural appearance on slit-lamp biomicroscopy. The
healthy gel in a young patient has a dense compact
homogenous lamella structure (fig. 2D). Ultrastructural
examination of the rabbit eye has shown that these la-
mellae reflect the organization of collagen fibrils within
the vitreous gel (Los et al. 1999). We have shown else-
where that families with a vestigial congenital mem-
branous anomaly of the vitreous consistently have mu-
tations in the COL2A1 gene (Snead et al. 1994). Recent
mutation detection in such families and sporadic cases
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Figure 5 COL2A1 cDNA sequencing. Sequencing of cDNA
amplified from an individual (MS20 C) with a nonsense mutation
in exon 42 showed loss of heterozygosity when compared with the
genomic sequence (MS20 G). Amplified cDNA from MS16 and
MS25 showed heterozygosity for the mutations seen in genomic DNA
(fig. 1).
Figure 6 Position of ArgrCys substitutions in fibrillar colla-
gens. The position of cysteine substitutions in the a1(I), a1(II), and
a2(XI) collagens are illustrated. X-position changes are indicated be-
low the line representing each molecule, whereas Y-position changes
are indicated above the lines. Numbers represent the amino acid po-
sition within the helix. The resulting phenotypes are osteoarthritis
(OA), spondyloepipheseal dysplasia (SED), SED congenita (SEDC),
Stickler syndrome (SS), mild chondrodysplasia (MC), Stickler-like syn-
drome (SLS), classical Ehlers-Danlos syndrome (CEDS), and nonsyn-
dromic deafness (DFN).
in which linkage analysis was not possible has now
confirmed this finding (Richards et al. 2000; authors’
unpublished data). Families withmutations inCOL11A1
have a different vitreous phenotype, of sparse, irregu-
larly thickened lamellae (fig. 2B; Richards et al. 1996;
Martin et al. 1999; Snead and Yates 1999). The family
described here (MS25) was unique in that genetic anal-
ysis linked the disorder to COL2A1, but the vitreous
appearance was different from that seen in other fam-
ilies with COL2A1mutations. The pedigree also lacked
the “string of pearls,” or beaded, appearance caused by
mutations in COL11A1. Here we have shown that this
family has a L467F substitution in the X position of
the type II collagen Gly-X-Y triple helix. Taken together,
the linkage data, absence of other amino acid substi-
tutions, lack of nonsense-mediated decay, and the mu-
tation’s absence in normal chromosomes indicate that
the L467F COL2A1 change described here is the caus-
ative mutation in this family. We have also shown that
an additional X-position mutation (R365C) causes
Stickler syndrome, but with the vitreous phenotype usu-
ally associated with premature termination codons in
COL2A1.
Similar X- and Y-position Arg-Cys substitutions (fig.
6) have been described in types I, II, and XI collagen
(Ala-Kokko et al. 1990; Chan et al. 1993; Williams et
al. 1993; Ballo et al. 1998; McGuirt et al. 1999; Nuy-
tinck et al. 2000). It now seems clear that this type of
amino acid substitution in the fibrillar collagens results
in connective-tissue disorders. Evidence for other X- or
Y-position mutations causing disease is scarce. A Y-po-
sition R618Q substitution in a1(I) collagen resulted in
abnormal migration of the protein in gel electrophoresis
(Philips et al. 1990). This change was seen in a woman
with features of Marfan syndrome, although the fea-
tures were less pronounced in her father, who also had
the change. Marfan syndrome has since been linked to
mutations in fibrillin (Dietz et al. 1991), and it is unclear
whether the amino acid substitution caused all of the
clinical phenotype. A short report also described a
R618H change in a2(I) collagen (Superti-Furga et al.
1994) but concluded that at most it caused “connective
tissue weakness.” A similar report described a a1(III)
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L2F change in an individual with late-onset aneurysms
(Anderson et al. 1994). Because of the sporadic nature
of this latter case, it was unclear whether the change in
COL3A1 was causative, but its similarity to the L467F
mutation described here is interesting.
The R365C mutations described here have arisen
independently and appear to be a mutational hot-
spot, similar to other ArgrCys mutations that occur in
COL2A1 (Ala-Kokko et al. 1990; Eyre et al. 1991;
Holderbaum et al. 1993; Williams et al. 1993, 1995;
Reginato et al. 1994). These cysteine substitutions have
been identified in cases of either precocious osteoar-
thritis/mild SED/SED congenita (Y position) or a Stick-
ler-like syndrome (X position). The family with Stickler
syndrome also had brachydactyly, which may be due to
the C-terminal location of the mutation rather than to
its X position in the Gly-X-Y repeat, since neither of
the patients with R365C mutations reported here has
this trait.
The differing appearances that the R365C and L467F
mutations cause in the vitreous suggests that they are
having a different effect on the amount of type II col-
lagen available for gel formation. Both of the R365C
mutations resulted in the same vitreous phenotype that
was, because of premature termination codons, seen in
Stickler syndrome. Our working hypothesis for the
vitreous phenotypes seen with Stickler syndrome’s
COL2A1 and COL11A1mutations is that, at a specific
stage of fetal eye development, a critical mass of col-
lagen is required for proper formation of the secondary
vitreous. Haploinsufficiency of type II collagen results
in this threshold not being met, and only a vestigial gel
forms in the retrolental space. This anomaly is congen-
ital and appears to be clinically static, suggesting that
subsequent accumulation of type II collagen cannot
compensate for this stage-specific shortfall in the ma-
jor constituent of the vitreous. Type XI collagen is a
quantitatively minor component, and mutations in
COL11A1 do not stop the bulk formation of the vit-
reous gel. However, because of the role of type XI col-
lagen in the control of fibril diameter, COL11A1 mu-
tations result in abnormal fibrillogenesis, andwe suggest
that this is reflected in the variability of lamella bundle
organization seen on slit-lamp examination of the vit-
reous. In these cases, irregularly thickened fiber bundles
are seen, indicating a reduction in the level of type XI
collagen, compared with type II collagen, allowing fi-
brils of irregular diameter to form. The a3 chain of type
XI collagen is transcribed from the COL2A1 gene (Wu
and Eyre 1995). However, because expression of type
II collagen is much higher than that of type XI, it is
unclear whether COL2A1 haploinsufficiencymutations
will affect type XI collagen and, subsequently, the la-
mellar morphology. Such an effect would be difficult
to distinguish by slit-lamp examination, since, in these
cases, the vitreous gel is so abnormal.
Previous studies (Eyre et al. 1991) have shown that
the type II collagen R519C substitution reduces the
amount of protein secreted, therefore reducing the
amount of collagen available for matrix assembly. Sim-
ilarly, theCOL1A1,X-position, R134Cmutation (Nuy-
tinck et al. 2000) has been shown to form disulfide-
bonded collagen dimers, which were not secreted by
cultured cells. A skin biopsy from this patient also
showed dilatation of the rough endoplasmic reticulum,
indicating retention of mutant collagen within the cell.
A mutation of glycine to cysteine in type II collagen also
formed dimers and was poorly secreted (Mundlos et al.
1996). Because the COL2A1 R365C mutations de-
scribed here both resulted in the phenotype associated
with haploinsufficiency, this suggests that this mutation
also causes a reduction in secretion of type II collagen,
which disrupts secondary vitreous embryogenesis. As
yet, we have only limited tissue available to test this
hypothesis or to perform ultrastructural studies.
In MS25, the vitreous appears to fill the entire pos-
terior segment, but with an appearance different from
that seen in families with COL11A1 mutations. The
lack of the type 1 vitreous anomaly suggests that, for
the L467F mutation, the amount of collagen available
for gel formation is greater than both that for the
R365C change and that in cases of haploinsufficiency.
The relatively mild systemic features seen in this family
also suggest that the L467F change has less of an effect
than does haploinsufficiency. The mutation in MS25
will be incorporated into both types II and XI colla-
gen, although, because of the stochiometry of chain
composition, it will be expected to affect each to a dif-
ferent extent. In the homotrimeric type II collagen,
a1(II)3, 7/8 of molecules will contain at least onemutant
a chain, whereas only half of the molecules of type XI
heterotrimer collagen, a1(XI)a2(X)a1(II), will contain
a mutant a chain. Other forms of type XI collagen exist
in the eye, including a1(XI)2a1(V) (Mayne et al. 1993);
these molecules will be unaffected by mutations in
COL2A1. In MS25, the vitreous is diaphanous and de-
void of the normal fibrillar lamellar structure. A widely
observed effect of mutations that disrupt collagen hel-
ices is reduced secretion of the mutant protein (Prockop
and Kivirikko 1995). However, at present it is unclear
whether the vitreous phenotype in MS25 is due to al-
tered secretion of mutant type II collagen or whether
the mutation changes the process of fibrillogenesis. If
secretion of the mutant L467F collagen is reduced, the
change will affect type II collagen more than it affects
type XI, because of the chain stochiometry of the dif-
ferent molecules. Thus, the vitreous phenotype may be
due to an increase in the ratio of type XI to type II
collagen, resulting in thinner structures not easily seen
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by slit-lamp examination. Alternatively, the mutation
may either disrupt association between collagen mole-
cules or affect interaction with other components of the
vitreous extracellular matrix. Ultrastructural studies of
tissue from these patients will be necessary to determine
changes to collagen-fiber diameter and conformation.
In summary, we have shown that dominant negative
mutations in COL2A1 can result in Stickler syndrome.
An R365C substitution resulted in the same vitreous
phenotype as was seen in cases of haploinsufficiency,
and with similar systemic features. A novel and uni-
que mutation in COL2A1, L467F, caused a differ-
ent afibrillar vitreous. This contrasted with the thick-
ened beaded bundles seen elsewhere in patients with
COL11A1 mutations. Patients with this mutation had
only mild systemic features, but, in both groups, ocular
features were severe, including extreme myopia and bi-
lateral retinal detachment.
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